§ 185-42. Biotechnology uses.

A. 

Purpose. The purpose of this section is to protect the public from risks and potential risks posed by biotechnology uses in the Town of Franklin, including but not limited to experimentation with or use of recombinant DNA (rDNA) technology.

B. 

Use limitations and conditions. Biotechnology uses are allowed subject to the following limitations and conditions:

(1) 

Biotechnology uses are permitted within the Biotechnology Use Zoning District delineated on the maps entitled "Town of Franklin Biotechnology District 1A" and dated January 4, 2010, and "Town of Franklin Biotechnology District 1B" and dated November 6, 2009, appended to this Zoning Bylaw and on file with the Town Clerk and the Building Commissioner.

(2) 

Use, storage or experimentation with hazardous infectious agents, including but not limited to agents developed through rDNA technology, that are classified by National Institute of Health guidelines as requiring Biosafety Level 4 (BSL-4) containment are not permitted in the Town of Franklin.

(3) 

All biotechnology uses shall comply with the Guidelines for Research Involving DNA Molecules as promulgated by the National Institutes of Health (NIH) of the United States Department of Health and Human Services and published in the Federal Register on May 7, 1986, and any subsequent amendments.

(4) 

All biotechnology uses within the Town of Franklin shall comply with Franklin Board of Health Biotechnology Regulations, Chapter 198 of Franklin's Town Code.

(5) 

A Franklin Board of Health biotechnology operating protocol permit shall be obtained prior to commencing a biotechnology use or constructing any structure for such use.

(6) 

Supplemental site plan submittal requirements. Where biotechnology use is proposed and site plan review approval is required, all approved site plans will contain the following condition: A Franklin Board of Health biotechnology operating protocol permit shall be obtained prior to commencing a biotechnology use or constructing any structure for such use.

(7) 

Municipal sewer service must be available and the applicant shall be required to connect.

(8) 

Biomedical waste products or by-products shall not be discharged through the municipal sewer system unless all viable microorganisms, whether containing recombinant DNA or not, have been rendered noninfectious in accordance with 105 CMR 480.

Editor's Note: Former § 185-42, Development rate limitation, added 10-8-1986 by Bylaw Amendment 86-72, was repealed 10-4-1989 by Bylaw Amendment 89-168.

Added 11-3-1993 by Bylaw Amendment 93-245; 7-9-2008 by Bylaw Amendment 08-618; 3-17-2010 by Bylaw Amendment 10-640